Fermer le menu


Member of Lyonbiopole


TOLLYS develops new ligands of Toll Like Receptor 3 (TLR3)as specific immunotherapies with immunological induced memory in the field of cancer (personnalized vaccines). TOLLYS is actually seeking for funds to perform preclincal studies and go through phase I clinical study.


Strategic application domain: Human Medicine

Application market: Oncology

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Molecular Biology & Nucleic acid, Vaccine

Created on july 2nd, 2015 - 13 employees



60 F avenue Rockefeller 69008 LYON 08



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.